Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NM-IL-12 Compassionate Use for Localized Radiation Skin Injury
jRCTs031230407Recruiting
- Sponsor
- Libo Pharma Corp.
- Start
- Oct 2023
- Modality
- Cytokines & Interferons → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Open-label trial of HemaMax in radiodermatitis (2 arms), sponsored by Libo Pharma Corp. Primary endpoint: Time to occurrence or worsening of radiation-induced skin damage. Started Oct 2023; status: recruiting.
02
Drugs
HemaMax
03
Conditions
radiodermatitis
Beyond the preview
Go deeper on jRCTs031230407.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCTs031230407.